ADAPTIVE BIOTECHNOLOGIESLOGIES CORP
ADAPTIVE BIOTECHNOLOGIESLOGIES CORP
Aktie · US00650F1093 · ADPT · A2PLR5 (XNAS)
Übersicht Finanzkennzahlen
10,09 USD
4,34 % 0,42 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 20:00

Aktuelle Kurse von ADAPTIVE BIOTECHNOLOGIESLOGIES CORP

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
ADPT
USD
06.06.2025 20:00
10,09 USD
9,87 USD
+2,23 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 4,99 % 14,53 % 37,28 % 60,93 % 179,50 % -73,95 %

Firmenprofil zu ADAPTIVE BIOTECHNOLOGIESLOGIES CORP Aktie

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Investierte Fonds

Folgende Fonds haben in investiert: ADAPTIVE BIOTECHNOLOGIESLOGIES CORP investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
182,24
Anteil (%)
0,43 %

Unternehmensdaten

Name ADAPTIVE BIOTECHNOLOGIESLOGIES CORP
Firma Adaptive Biotechnologies Corporation
Symbol ADPT
Website https://www.adaptivebiotech.com
Heimatbörse XNAS NASDAQ
WKN A2PLR5
ISIN US00650F1093
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Chad M. Robins M.B.A.
Marktkapitalisierung 1 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,6 T
Adresse 1165 Eastlake Avenue East, 98109 Seattle
IPO Datum 2019-06-27

Ticker Symbole

Name Symbol
Frankfurt 1HM.F
NASDAQ ADPT

Weitere Aktien

Investoren die ADAPTIVE BIOTECHNOLOGIESLOGIES CORP die halten, haben auch folgende Aktien im Depot:
ABBOTT LABORATORIES INC
ABBOTT LABORATORIES INC Aktie
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Aktie
BASF SE
BASF SE Aktie
EDITAS MEDICINE INC
EDITAS MEDICINE INC Aktie
ILLUMINA INC
ILLUMINA INC Aktie
INTELLIA THERAPEUTICSCS INC
INTELLIA THERAPEUTICSCS INC Aktie
INVESTEC BANK PLC EUR IMPALA KO NTS CAR 18/06/24
INVESTEC BANK PLC EUR IMPALA KO NTS CAR 18/06/24 Anleihe
ISHS CORE DAX UCITS ETF
ISHS CORE DAX UCITS ETF ETF
SINOP.G.O.D.17 17/47 REGS
SINOP.G.O.D.17 17/47 REGS Anleihe
TOTALENERGIES SE  EO 2,50
TOTALENERGIES SE EO 2,50 Aktie
VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INC Aktie
VISA INC - CLASS A
VISA INC - CLASS A Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025